Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Axsome Therapeutics, Inc. - Common Stock
(NQ:
AXSM
)
164.08
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Earnings Scheduled For February 18, 2025
↗
February 18, 2025
Via
Benzinga
Beyond The Numbers: 17 Analysts Discuss Axsome Therapeutics Stock
↗
February 10, 2025
Via
Benzinga
12 Analysts Have This To Say About Axsome Therapeutics
↗
January 21, 2025
Via
Benzinga
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
↗
February 16, 2025
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via
Benzinga
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
↗
February 16, 2025
Via
The Motley Fool
Why Axsome Therapeutics Stock Is Soaring Today
↗
February 11, 2025
Via
The Motley Fool
Why Axsome Therapeutics Stock Is Skyrocketing Today
↗
February 10, 2025
Via
The Motley Fool
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
↗
February 10, 2025
Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.
Via
Benzinga
Topics
Intellectual Property
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
↗
December 30, 2024
Via
Benzinga
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics
↗
November 12, 2024
Via
Benzinga
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
↗
February 10, 2025
Via
Benzinga
Axsome Stock Rockets To Record High After Settling With Teva Over Depression Drug, Retail Optimism Swells
↗
February 10, 2025
Under the settlement terms, Teva will receive a license to sell a generic version of Auvelity starting March 31, 2039, if pediatric exclusivity is granted.
Via
Stocktwits
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
February 10, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
January 31, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
January 30, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
January 22, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
↗
January 17, 2025
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Via
Investor's Business Daily
Topics
Economy
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
January 13, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
↗
December 31, 2024
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025.
Via
Benzinga
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation
↗
December 30, 2024
Shares of dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.
Via
Investor's Business Daily
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
December 30, 2024
Via
Benzinga
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
December 30, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
↗
November 27, 2024
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.
Via
Benzinga
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
November 26, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
↗
November 12, 2024
AXSM earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
November 08, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
October 29, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
↗
October 19, 2024
Yes, bargains can still be found in the stock market.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
